IBS-C Management: Circadian Rhythms and SIBO

For individuals with irritable bowel syndrome with constipation (IBS-C), the search for effective symptom control can be a persistent challenge. New research points to two distinct but important management areas: aligning eating patterns with circadian rhythms and addressing underlying small intestinal bacterial overgrowth (SIBO).

Time-Restricted Eating Led to a 125-Point Symptom Drop in IBS-C Patients

A 2026 pilot study from Kristiania University College provides compelling preliminary data on a simple behavioral intervention. Researchers enrolled 134 IBS patients who then followed an 8-week protocol of time-restricted eating (TRE), confining all food intake to an 8-hour daily window followed by 16 hours of fasting. Of the 97 who completed the study, the overall average reduction on the IBS Symptom Severity Scale (IBS-SSS) was 100.2 points, a statistically significant result.

The most striking finding was for the IBS-C subgroup. These participants reported a mean symptom reduction of 125.2 points. For context, a 50-point drop on the IBS-SSS is considered clinically meaningful; these results suggest a substantial potential benefit. Study authors Clausen, Sverdrup, and colleagues also noted improvements in self-reported physical and mental health. It is important to acknowledge this was a single-group, pre-post study without a control group, so placebo effects cannot be ruled out. However, the magnitude of change warrants serious attention and controlled trials, as the authors conclude. More details on this specific study can be found in our article, Time-Restricted Eating Eases IBS-C Symptoms in Study.

How a Daily Fasting Window May Reshape Gut Function

The mechanism behind TRE’s potential benefit for IBS-C likely connects to circadian biology and gut motility. The gastrointestinal tract has its own circadian clock that regulates enzyme secretion, gut barrier function, and the migrating motor complex (MMC). The MMC is a series of cleansing waves that sweep through the small intestine during fasting states, clearing debris and bacteria.

A shortened or erratic eating window can disrupt these rhythms and suppress the MMC. By establishing a consistent, prolonged daily fast—such as the 16-hour period used in the study—the gut is given a predictable and adequate period to complete this housekeeping. This may reduce bacterial buildup, improve intestinal flow, and alleviate bloating and constipation. Furthermore, TRE may promote a more stable and resilient gut microbiome by reducing the constant influx of nutrients that feed fermenting bacteria.

Rifaximin Shows Efficacy for Overlapping SIBO and IBS Symptoms

Constipation in IBS is not always isolated. A 2026 systematic review by Shah and Soldera examined antibiotic treatments for SIBO and IBS, noting the significant symptom overlap between the two conditions. While SIBO is classically associated with diarrhea and bloating, a methane-predominant variant is strongly linked to constipation.

The review found that the non-systemic antibiotic rifaximin is frequently effective in treating hydrogen-dominant SIBO and associated IBS-D symptoms. For constipation-predominant cases, the evidence is more complex, often requiring combination therapy targeting methane-producing archaea. This highlights a critical management point: a subset of IBS-C patients may have an underlying SIBO component driving their symptoms. Successfully treating this overgrowth with a targeted antibiotic like rifaximin can lead to major symptom relief. A comprehensive overview of this condition is available in our SIBO Complete Guide.

Integrating Timing and Targeted Treatment into Personal Management

These research threads point to a two-pronged practical approach for managing IBS-C. First, consider the timing of eating. Adopting a consistent TRE schedule, such as eating between 12 PM and 8 PM, is a low-risk strategy that may synchronize gut rhythms and motility. Patients in the pilot study saw benefits within 8 weeks. It requires no special foods or supplements, only a adjustment of meal timing.

Second, for individuals whose constipation is resistant to dietary and lifestyle changes, assessment for SIBO is a logical step. A positive breath test, particularly one indicating methane, can guide a targeted treatment plan with a gastroenterologist, potentially involving rifaximin. It is essential to pair any antibiotic treatment with prokinetic agents and dietary strategies to help prevent recurrence, as relapse rates can be high. Personalized management is key, as explored in our resource on New IBS-C Treatments.

Managing IBS-C effectively may require looking beyond fiber and laxatives. Evidence suggests aligning food intake with the body’s natural fasting cycles can significantly reduce symptom severity. Concurrently, screening for and treating SIBO with antibiotics like rifaximin addresses a common physiological driver. Together, these strategies offer a more nuanced framework for gaining control over persistent constipation.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41829935/
https://pubmed.ncbi.nlm.nih.gov/41809172/